{"source":"kalshi","id":"KXATACICEPT-26","ticker":"KXATACICEPT-26","slug":"KXATACICEPT-26","title":"FDA decision: Atacicept by Vera Therapeutics (in July 2026)","description":null,"image":null,"icon":null,"active":true,"closed":false,"start_date":"2026-06-17T21:00:00Z","end_date":"2026-08-08T14:00:00Z","closed_time":null,"volume":743.12,"volume_24hr":0.81,"volume_24h_change":null,"normalized_vol_24hr":0.11377648264169693,"normalized_volume":12.40602970123291,"liquidity":null,"open_interest":704.96,"categories":["Finance"],"tags":[],"synthetic":false,"is_group":false,"group_key":null,"parent_event_id":null,"probability":null,"spread":null,"top_outcome":"a full approval or an accelerated approval","top_outcome_probability":0.85,"top_outcome_prob_24h_change":-0.06000000000000005,"top_outcome_volume_24h_change":0.0,"updated_at":"2026-07-02T16:42:51.094680Z","fetched_at":"2026-07-02T16:42:51.094680Z","added_at":"2026-06-17T21:13:56.751406Z","url":"https://kalshi.com/markets/kxatacicept/fda-decision-atacicept-by-vera-therapeutics-in-july-2026/kxatacicept-26","chart_24h":[0.0,0.81],"markets":[{"source":"kalshi","id":"KXATACICEPT-26-Y","event_id":"KXATACICEPT-26","slug":"KXATACICEPT-26-Y","question":"What will the FDA's decision be on Atacicept by Vera Therapeutics in July 2026?","group_item_title":"a full approval or an accelerated approval","description":"If the FDA's decision on Atacicept by Vera Therapeutics in July 2026 is a full approval or an accelerated approval, the market resolves to Yes.\n\n---\n\nThis market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. \n\nAtacicept is an investigational biological medicine developed by Vera Therapeutics that acts as a \"double interceptor,\" blocking two proteins — called BAFF and APRIL — that instruct the immune system's B cells to overproduce a defective form of the antibody IgA. Think of BAFF and APRIL as two fuel lines feeding an immune fire in the kidney; atacicept is designed to shut off both simultaneously, dampening the abnormal immune response that drives kidney damage in IgA nephropathy (IgAN).","image":null,"icon":null,"outcomes":["Yes","No"],"outcome_prices":[0.85,0.15000000000000002],"probability":0.85,"spread":0.050000000000000044,"active":true,"closed":false,"start_date":"2026-06-17T21:00:00Z","end_date":"2026-08-08T14:00:00Z","closed_time":"2026-08-01T03:59:00Z","volume":743.12,"volume_24hr":0.81,"prob_24h_change":-0.06000000000000005,"volume_24h_change":0.0,"normalized_vol_24hr":0.12144894897937775,"normalized_volume":12.930807113647461,"liquidity":null,"categories":["Finance"],"countries":["United States"],"updated_at":"2026-07-02T20:38:34.171043Z","fetched_at":"2026-07-02T20:38:34.171043Z","added_at":"2026-06-17T21:13:57.021144Z","url":"https://kalshi.com/markets/kxatacicept/fda-decision-atacicept-by-vera-therapeutics-in-july-2026/kxatacicept-26","event_title":"FDA decision: Atacicept by Vera Therapeutics (in July 2026)","chart_24h":[0.91,0.91,0.91,0.91,0.91,0.91,0.91,0.85,0.85,0.85,0.85]}],"_meta":{"attribution":"pdata.world — aggregated prediction-market data across 8 platforms","canonical_url":"https://pdata.world/events/kalshi/KXATACICEPT-26","as_of":"2026-07-02T22:06:56.804899Z","docs":"https://api.pdata.world/docs","cite_as":"According to pdata.world (tracking Kalshi): \"FDA decision: Atacicept by Vera Therapeutics (in July 2026)\" — top market at 85% probability across 1 outcome","source_url":null}}